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ABSTRACT Development of nonalcoholic fatty liver disease (NAFLD) occurs through initial steatosis and subsequent
oxidative stress. The aim of this study was to examine the effects of a-lipoic acid (LA) on methionine–choline deficient
(MCD) diet-induced NAFLD in mice. Male C57BL/6 mice (n = 21) were divided into three groups (n = 7 per group): (1)
control fed with standard chow, (2) MCD2 group—fed with MCD diet for 2 weeks, and (3) MCD2+LA group—2 weeks on
MCD receiving LA i.p. 100 mg/kg/day. After the treatment, liver samples were taken for pathohistology, oxidative stress
parameters, antioxidative enzymes, and liver free fatty acid (FFA) composition. Mild microvesicular hepatic steatosis was
found in MCD2 group, while it was reduced to single fat droplets evident in MCD2 +LA group. Lipid peroxidation and
nitrosative stress were increased by MCD diet, while LA administration induced a decrease in liver malondialdehyde and
nitrates + nitrites level. Similary, LA improved liver antioxidative capacity by increasing total superoxide dismutase (tSOD),
manganese SOD (MnSOD), and copper/zinc-SOD (Cu/ZnSOD) activity as well as glutathione (GSH) content. Liver FFA
profile has shown a significant decrease in saturated acids, arachidonic, and docosahexaenoic acid (DHA), while LA treatment
increased their proportions. It can be concluded that LA ameliorates lipid peroxidation and nitrosative stress in MCD diet-
induced hepatic steatosis through an increase in SOD activity and GSH level. In addition, LA increases the proportion of
palmitic, stearic, arachidonic, and DHA in the fatty liver. An increase in DHA may be a potential mechanism of anti-
inflammatory and antioxidant effects of LA in MCD diet-induced NAFLD.
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INTRODUCTION
Methionine–choline deficient (MCD) diet iswidely used for the development of nonalcoholic fatty
liver disease (NAFLD) and nonalcoholic steatohepatitis
(NASH) animal model.1 NAFLD includes a wide spectrum
of liver diseases ranging from simple steatosis to steatohe-
patitis and cirrhosis, which often progress to hepatocellular
carcinoma (HCC).2 The earliest stage of NAFLD is simple
hepatic steatosis, which is characterized by deposition of
triglycerides in more than 5% of hepatocytes. Hepatic stea-
tosis can progress to NASH and about 20% of patients with
NASH develop cirrhosis, while about 28% of patients with
NASH-induced cirrhosis develop hepatocellular carcino-
ma.3 Nowadays, the prevalence of NAFLD increases rapidly
parallel with obesity and diabetes.
Mechanisms involved in the progression of steatosis to
NASH are complex and not completely understood. Insulin
resistance, oxidative stress, inflammation, and innate im-
mune system activation contribute to the development of
NAFLD through steatosis and inflammation in the liver.4
Although still poorly understood, the pathogenesis of
NAFLD is widely explained by a two-hit model theory in
which the first hit is an initial metabolic disturbance that
increases the inflow of free fatty acids (FFAs) and de novo
lipogenesis, leading to steatosis. Triglyceride accumulation
in hepatocytes increases the sensitivity of the liver to sec-
ondary insults (the ‘‘second hit’’), which include oxidative
stress, decreased hepatic ATP production, and induction of
proinflammatory cytokines.5,6 Many studies on animals and
humans have shown correlation between severity of NASH
and oxidative stress degree.7,8
Various animal models of NAFLD/NASH were used in
previous studies, and they may be classified into genetic
models, nutritional models, and their combinations. Al-
though numerous animal models are used, neither com-
pletely reflects pathophysiology and liver histopathology of
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human NAFLD/NASH.9 One commonly used model is
treatment with CCL4 (carbon-tetrachloride). CCl4-induced
toxicity and its mechanisms have been extensively investi-
gated after oral administration to rodents. A large number of
rat models have been reported to develop both liver cirrhosis
and HCC using CCl4 or diethylnitrosamine.
10 CCl4 is a
well-known compound for the production of chemical he-
patic injury which is mediated by metabolites that react with
antioxidant enzymes, such as glutathione (GSH), catalase
(CAT), and superoxide dismutase (SOD), and increase the
level of inflammatory cytokines,11 which make this model
of liver injury suitable for investigation of antioxidant ac-
tivity in vivo.
Recently, the role of lipotoxicity was emphasized in the
pathogenesis of NAFLD. Lipotoxicity is known to promote
hepatocyte death, which in the context of NAFLD is termed
lipoapoptosis.12 Lipoperoxides generated by the reaction of
free radicals with membrane fatty acids can induce hepa-
tocyte membrane damage. The fatty acid profile may in-
fluence the formation of lipoperoxides, as it is known that
unsaturated fatty acids are more susceptible to oxidative
modification than are saturated fatty acids.
a-Lipoic acid (LA) is a natural compound, chemically
named 5-(1,2-dithiolan-3-yl) pentanoic acid, that is also
known as thioctic acid. In humans, LA is synthesized in the
liver and other tissues with high metabolic activity, such as
the heart and kidney. It is also synthesized in small amounts
by plants.13 Previous studies have suggested that LA can
improve liver antioxidant defense in rats.14 LA has reactive
oxygen species scavenging capacity, the capacity to regen-
erate endogenous antioxidants, such as GSH, and vitamins E
and C, and a metal-chelating capacity.15 Unlike other anti-
oxidants, LA is both water and lipid soluble and, therefore,
can cross biological membranes easily and has its antioxi-
dant action both in the cytosol and in the plasma
membrane.16
Although the direct antioxidative role of LA was con-
firmed, its indirect effects on the course of NAFLD through
changes in liver fatty acid profile are not completely clear. A
possible link between fatty acid profile and antioxidative
properties of LA may have potential beneficial effects in the
prevention of steatosis progression into NASH. Therefore,
the aim of this study was to examine the effects of LA
treatment on liver oxidative stress parameters, FFA com-
position, and pathohistology in MCD diet-induced NAFLD
in mice.
MATERIALS AND METHODS
Animals
The experiment was performed on male C57BL/6 mice,
weighing on average 23– 3 g, raised at Military Medical
Academy in Belgrade. Animals were housed individually in
a controlled laboratory environment (temperature 22C –
2C, relative humidity 50% – 10%, 12/12 h light-dark cycle
with lights turned on at 9:00 h a.m.). All experimental pro-
cedures were in full compliance with Directive of European
Parliament and of the Council (2010/63EU) and approved
by the ethics committee of the University of Belgrade
(no. 695/2).
All animals (n = 21) were on standard chow before the
experiment. At the age of 8 weeks, they were randomly
divided into the following groups: (1) control (C; n = 7)—
continuously fed with standard chow; (2) MCD2 group
(n = 7)—fed with MCD diet for 2 weeks, and (3) MCD2 +
LA group (n = 7)—fed with MCD diet and simultaneously
treated with a-LA (100 mg/kg daily i.p.) for 2 weeks.
Control diet contained 2 g/kg choline chloride and 3 g/kg
methionine, while MCD diet (MP Biomedicals) had the
same composition as control standard chow without methio-
nine and choline with the expense of sucrose (22.76%). Before
administration, LA (Sigma-Aldrich) was dissolved in saline in
a concentration of 10 mg/mL (injection volume 0.01 mL/g
body weight). All animals had free access to adequate food
and water during the experiment. During the diet, daily food
intake was measured, while body weight was measured
weekly and compared with liver weight after sacrifice.
After the treatment, animals were sacrificed by exsan-
guinations in ketamine (100 mg/kg i.p.) anesthesia. On the
day before sacrifice, mice were fasted overnight. Liver
samples were collected for pathohistological analysis, FFA
level measurement, determination of oxidative stress pa-
rameters, and antioxidative enzymes activity.
Sample preparation
Liver samples for biochemical analysis were homoge-
nized on ice in cold buffered 0.25 M sucrose medium
(Serva, Feinbiochemica) that contained 10 M phosphate
buffer (pH 7.0) and 1 mM EDTA (Sigma Chem. Co.). The
homogenates were centrifuged at 2000 g for 15 min at 4C.
Crude sediments were dissolved in a sucrose medium
and centrifuged. The supernatants were transferred into the
tubes and centrifuged at 3200 g for 30 min at 4C. Obtained
sediments were dissolved in deionized water. After 1 h of
incubation, the samples were centrifuged at 3000 g for
15 min at 4C, and supernatants were stored at - 70C.
Supernatants obtained were combined after three rounds of
centrifugation. Proteins were determined by the Lowry
method using bovine serum albumin as the standard.17
Biochemical analysis
Total SOD (tSOD; EC1.15.1.1) activity in the liver was
measured spectrophotometrically, as an inhibition of epi-
nephrine autooxidation at 480 nm. After the addition of
10 mM epinephrine (Sigma), an analysis was performed in
the sodium carbonate buffer (50 mM, pH 10.2; Serva,
Feinbiochemica) containing 0.1 mM EDTA (Sigma). Sam-
ples for manganese SOD (MnSOD) were previously treated
with 8 mM KCN (Sigma) and then analyzed as previously
described.18 Activity of copper/zinc-SOD (Cu/ZnSOD) was
calculated as a difference between the activities of total
SOD and MnSOD.
Lipid peroxidation in the plasma and liver homogena-
tes was measured as malondialdehyde (MDA) production,
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assayed in the thiobarbituric acid.19 The results are ex-
pressed as nM/mg protein in liver homogenates.
The concentration of nitrites + nitrates (NOx) as a mea-
sure of nitric oxide (NO) production was determined by
using Griess reagent. With nitrites, Griess reagent forms a
purple azo dye, which can be measured spectrophotomet-
rically at 492 nm.20
Reduced GSH was determined using 5,5-dithiobis-2-
nitrobenzoic acid (36.9 mg in 10 mL of methanol), which
had reacted with aliphatic tiol compounds in Tris-HCl buffer
(0.4 mol, pH 8.9), thus making yellow-colored p-nitrophenol
anion. Spectrophotometric measurement of GSH concen-
tration at 412 nm was proportioned to color intensity of the
chemical compound produced.21
CAT activity in the liver was determined spectrophoto-
metrically at 240 nm on the basis of decline of hydrogen
peorxide absorbance and was expressed as units per mg of
proteins in the sample.21,22 One unit was defined as a re-
duction of 1 lM H2O2 per minute at 25C, pH 7.
Pathohistological analysis
Liver tissue was sectioned and incubated in 10% formalin
solution at room temperature. After the fixation, the liver
samples were processed by the standard method. Tissues
were incorporated in paraffin, sectioned at 5 lm, and then
stained with hematoxylin–eosin. Then, they were prepared
for light microscopy analysis. All samples were evaluated
by an experienced pathohistologist who was blinded to
the experiment. Preparations were analyzed and photo-
graphed using a combined photobinocular light microscope
Olympus BX51-equipped Artcore 500 MI Artray, Co. Ltd.,
Japan Camera.
FFA analysis
Lipids for further fatty acid analysis were extracted ac-
cording to the Bligh and Dyer method.23 The methyl esters
of the fatty acids (FAMEs) from the lipid extract were
transesterified with HCl in methanol according to the
method described by Ichihara and Fukubayashi.24 FAMEs
were quantified using an Agilent Technologies 7890A Gas
Chromatograph with a flame ionization detector. Separation
of the FAMEs was performed on a 112-88A7, HP-88 cap-
illary column (100 m · 0.25 mm · 0.2 lm) using He as a
carrier gas at a flow rate of 105 mL/min. The samples were
injected at a starting oven temperature of 175C, injector
temperature was 250C, and detector temperature was
280C. The oven temperature was programmed to increase
from 175C to 220C at 5C/min. Fatty acids were identified
by their retention time with reference fatty acid standards
(Supelco FAME Mix) and were expressed as a percentage
of total fatty acids in the liver.
Statistical analysis
Results are expressed as means –SD. Since the normal
distribution of parameters was confirmed by Kolmogorov–
Smirnov test, one-way analysis of variance (ANOVA) with
Tukey’s post hoc test was used for testing the difference
among groups. The difference was considered statistically
significant if P < .05. Computer software SPSS 15.0 was
used for the statistical analysis.
RESULTS
During the experiment, no significant difference (P > .05)
in animal weight and daily food intake between groups was
found (data not shown).
Oxidative stress
Our results have shown significantly increased liver
MDA level in MCD2 group (398.02– 78.43 nmol/mg protein)
as compared with control (239.78–41.09 nmol/mg protein)
(P< .01). In contrast, MCD diet with LA treatment induced a
significant decrease in liver MDA level (93.56–22.06 nmol/
mg protein) as compared with control (P< .01) (Fig. 1A).
Similar to liver MDA level, MCD diet caused a signifi-
cant increase in liver NOx concentration (35.23– 4.78 nmol/
mg protein) when compared with control group (19.45–
6.02 nmol/mg protein) (P < .01). On the other hand, NOx
concentration was not significantly different between MCD2+
LA group and control (P> .05) (Fig. 1B).
CAT activity in the liver was significantly decreased in
both MCD2 (63.77– 13.85 U/mg protein) and MCD2 +LA
(56.36– 15.00 U/mg protein) groups as compared with
control (133.10– 40.54 U/mg protein) (P < .01), with no
significant difference (P > .05) between experimental groups
(Fig. 2).
The liver GSH content was significantly decreased 2
weeks after the initiation of MCD diet (102.44– 10.12 nmol/
mg protein) as compared with control (123.23– 12.32 nmol/
mg protein) (P < .05). In contrast to liver CAT activity, LA
treatment induced a significant increase in liver GSH con-
tent (154.87– 18.66 nmol/mg protein) when compared with
control and MCD2 group (P < .01) (Fig. 3).
MCD diet alone caused a significant decrease in liver total
SOD activity (2.95 – 1.40 U/mg protein) as compared with
control (27.96– 5.98 U/mg protein). However, in the group
treated with LA and MCD diet, total SOD activity was
significantly increased (55.08– 8.04 U/mg protein) when
compared with control and MCD2 group (P < .01).
Changes in total SOD activity were accompanied by the
same changes in MnSOD and Cu/ZnSOD activity. While
MCD diet alone provoked a significant decline in the ac-
tivity of both izoenzymes (1.62– 0.92 U/mg protein, and
1.33– 0.69 U/mg protein, respectively) as compared with
control (16.09– 2.49 U/mg protein and 13.16 – 2.46 U/mg
protein, respectively) (P < .01), the activities of MnSOD and
Cu/ZnSOD were significantly increased in MCD2 +LA
versus control group (29.60– 9.06 U/mg protein, and
33.56– 8.97 U/mg protein, respectively; P < .01) (Fig. 4).
Pathohistological analysis
No pathological changes were found in control group
(Fig. 5A). Mild hepatic steatosis with focal fatty change in
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the form of microvesicular steatosis was found in MCD2
group, accompanied with mild perivascular inflammation
(Fig. 5B). In MCD2 +LA group, steatosis and inflammation
were less pronounced than in MCD2 group with a few fat
droplets occasionally seen in hepatocytes (Fig. 5C).
FFA analysis
MCD diet induced a significant decrease in liver palmitic
(C16:0) and stearic acid (C18:0) proportion after 2 weeks as
compared with control (P < .01). Palmitic acid proportion
was, also, significantly lower in MCD2+LA group versus
control, but to a significantly lesser extent than in MCD2
group (P < .01). On the other hand, stearic acid proportion
was significantly higher in MCD2+LA versus. control
group (P < .05). While the proportion of oleic acid (C18:1
n9) was significantly higher, the proportion of oleic acid
isomer (C18:1 n7) was significantly lower in MCD2 group
when compared with control (P < .01). The combination of
LA and MCD diet induced no significant changes in liver
oleic acid isomer versus control group (P > .05). The pro-
portion of linoleic acid (C18:2 n6) was significantly higher
in MCD2 group versus control (P < .01), while in MCD2 +
LA group, the proportion of linoleic acid did not signifi-
cantly differ from the control (P > .05). When compared
with control group, arachidonic acid (C20:4 n6) was sig-
nificantly lower (P < .05) and docosapentaenoic acid (DPA,
C22:5 n3) was significantly higher (P < .01) in MCD2 group.
Similar to linoleic and oleic acid, in MCD2+LA group, no
significant difference in liver arachidonic acid and DPA was
found when compared with control (P > .05). In contrast, the
proportion of liver docosahexaenoic acid (DHA, C22:6 n3)
was not significantly changed in MCD2 group as compared
with control (P > .05), while LA treatment in combination
with MCD diet induced a significant increase in DHA when
compared with control (P < .05) (Table 1).
FIG. 1. Liver MDA level (A) and NOx concentration (B) in MCD
diet-treated mice and mice on MCD diet with LA administration.
(MCD2 and MCD2 +LA respectively). Since the normal distribution
of parameters was confirmed by Kolmogorov–Smirnov test, signifi-
cance of the difference was estimated by using one-way ANOVA
with Tukey’s post hoc test (**P< .01 vs. control). MCD, methionine–
choline deficient; LA, a-lipoic acid; MDA, malondialdehyde; NOx,
nitrates + nitrites; ANOVA, analysis of variance.
FIG. 2. Liver CAT activity after MCD diet treatment and MCD diet
with LA administration. Since the normal distribution of parameters
was confirmed by Kolmogorov–Smirnov test, significance of the
difference was estimated by using one-way ANOVA with Tukey’s
post hoc test (**P < .01 vs. control). For further information, see
Figure 1. CAT, catalase.
FIG. 3. Liver GSH content in mice treated with MCD diet with or
without LA administration. Since the normal distribution of param-
eters was confirmed by Kolmogorov–Smirnov test, significance of the
difference was estimated by using one-way ANOVA with Tukey’s
post hoc test (*P < .05, **P< .01 vs. control; ##P < .01 vs. MCD2
group). For further information, see Figure 1. GSH, glutathione.
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DISCUSSION
It is well known that oxidative stress contributes to liver
injury regardless of its etiology. Recently, many studies
have pointed to the antioxidant effects of LA.25 In accor-
dance with other studies of NAFLD,26 lipid peroxidation
and nitrosative stress were also accompanied with mild
steatosis in our study after MCD diet (Fig. 1). NO promotes
oxidative stress-induced cell injury by formation of perox-
ynitrite anion, a potent prooxidant that causes protein ni-
tration and tissue injury.27 Oxidative injury in MCD diet
model of NAFLD may be due to GSH depletion, as well as
to decline in CAT and SOD activity (Figs. 2–4). Poor ac-
tivity of CAT in both experimental groups may be poten-
tially due to secondary activated alternative GSH-pathways,
so the CAT could be more active in the early phase of the
model. The role of GSH depletion in the pathogenesis of
NAFLD is supported by many other studies.8,26 A decrease
in GSH/GSSG ratio reflects the shift of liver redox balance
toward pro-oxidants as well as decreased synthesis of GSH
due to methionine deficiency in the food. In addition,
increased NO production may also contribute to a decline in
intracellular GSH level and aggravation of cellular injury.28
Studies in experimental models and in the human popu-
lation suggest that FFAs may play an important role in the
pathogenesis of NAFLD.29 Recent data suggested that satu-
rated fatty acids have more severe lipotoxic and proapoptotic
effects in the liver than do unsaturated fatty acids.30,31
However, changes in liver FFA profile in NAFLD still
remain controversial. Some studies on patients with NAFLD
and NASH have shown that hepatic FFAs were unchanged
across the spectrum of liver injury,32 while plasma FFA
levels were significantly increased in NAFLD and they were
suggested to be the primary source for triglyceride (TAG)
synthesis in hepatocytes.33 On the other hand, a high fat diet
was found to induce an increase in liver DHA level in
mice.34 Our study has shown a decrease in hepatic saturated
(palmitic and stearic acid) and arachidonic acid proportions
in the group treated with MCD diet for 2 weeks.29,35
LA was found to have antioxidant effects, as well as to
affect lipid metabolism in the liver. It has been shown in
cultured rat hepatocytes that LA treatment significantly
FIG. 4. The effects of MCD diet and
LA treatment on tSOD, MnSOD, and
Cu/ZnSOD activity in mice liver. Since
the normal distribution of parameters
was confirmed by Kolmogorov–Smir-
nov test, significance of the difference
was estimated by using one-way AN-
OVA with Tukey’s post hoc test
(*P < .05, **P < .01 vs. control;
##P< .01 vs. MCD2). For further in-
formation, see Figure 1. tSOD, total
superoxide dismutase; MnSOD, man-
ganese SOD; Cu/ZnSOD, cuprum/zinc
SOD.
FIG. 5. Histological findings of liver tissue (hematoxylin and eosin,· 10). Control (A) group shows normal morphology of the liver. In MCD2
group (B), microvesicular hepatic steatosis with focal fatty change was observed with mild perivascular inflammation. In MCD2+LA group (C),
reduced steatosis with single fat droplets was evident with reduced inflammatory infiltrate. Color images available online at www.liebertpub.com/jmf
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inhibited FFA oxidation or reduced it even by 82%. In the
same study, it was also suggested that LA at therapeutic
concentrations increased pyruvate oxidation by activation of
the pyruvate dehydrogenase complex and decreased gluco-
neogenesis.36 In addition, LA treatment of insulin-resistant
rats for 14 weeks decreased plasma FFA concentrations and
this effect appears to be mediated, in part, by increased
hepatic PPAR-a expression, which may beneficially affect
insulin resistance.37
In our study, LA diminished MCD diet-induced lipid
peroxidation and nitrosative stress, probably due to in-
creased GSH level and SOD activity (Figs. 3 and 4). Similar
effects of LA were found in heart and kidney tissues,27 but
the effects on GSH level was found to be most marked in the
liver because of high activity of GSH-synthesizing enzymes
in this organ.38,39 However, the antioxidant effects of the LA
in NAFLD may be potentially due to its direct inhibition of
the free radicals (in the case of peroxinitrites), rather than
increased expression of the antioxidant enzymes. The anti-
oxidative effects of LA may be potentially mediated by
changes in fatty acid profile. n-3 Polyunsaturated fatty acids
may reduce oxidative damage and restore free radical ho-
meostasis by incompletely understood mechanisms.11 It has
been shown that linoleic, eicosapentaenoic acid (EPA), and
DHA have beneficial effects on oxidative stress in the kid-
neys by reducing MDA level, and increasing SOD and CAT
activity.40,41 However, our study suggests only the role of
DHA, and not of linoleic acid as a mediator of antioxidative
effects of LA in the liver, as only the proportion of DHA
increases after LA administration (Table 1). This possibly
indicates that supplementation of DHA, but not all poly-
unsaturated acids may potentiate the hepatoprotective ef-
fects of LA in NAFLD.
Other studies have also shown that supplementation with
DHA significantly reduced NO content and increased SOD
and CAT activity in the liver and brain. DHA supplemen-
tation improves cognitive functions and delays the onset of
pentylenetetrazole-induced seizures, at least partly through
attenuation of oxidative stress. In addition, DHA positively
modulates phosphatidylserine biosynthesis and accumula-
tion in neuronal cells, increases cell membrane fluidity, and
inhibits apoptosis in a phosphatidylserine-dependent man-
ner.42 The effects of DHA on membrane lipid composition
in the liver has to be further investigated, but these effects
may potentially contribute to modulation of oxidative stress
in NAFLD after LA treatment found in our study.
Arachidonic acid was, also, found to cause an increase in
MnSOD, Cu/ZnSOD, and CAT activities in rat hippocampal
slices.43 Since LA prevented MCD diet-induced decline in
arachidonic acid level in the liver, this can possibly be an
additional indirect mechanism of LA antioxidant effect.
However, this effect has to be further investigated by sup-
plementation with arachidonic acid using various models of
NAFLD.
Apart from influence on polyunsaturated fatty acids, an-
tioxidant effects of LA may be potentially further mediated
by an elevation of stearic acid proportion in the liver (Table
1). This may be surprising, as saturated fatty acids were
found to contribute to the apoptosis of hepatocytes and to the
progression of NAFLD, but stearic acid treatment has been
shown to increase the activity of SOD, especially Cu/
ZnSOD izoenzyme, CAT, and GSH peroxidase.44 This can
be considered one of the potentially beneficial effects of
stearic acid in NAFLD.
The effects of LA on liver fatty acid profile may, also, be
responsible for the anti-inflammatory effects of LA in
NAFLD found in the present study. n-3 Polyunsaturated fatty
acids reduce the inflammation in the liver through stimulation
of resolvin and protectin synthesis, as well as through inhi-
bition of phospholipase A2, an initial enzyme in the synthesis
of prostaglandins and leukotrienes. In addition, palmitic acid
increases the hepatocyte sensitivity to the cytotoxic effects of
TNF-a.45 DHA also exerts anti-inflammatory effect in the
brain through reduction of microglial secretion of proin-
flammatory cytokines such as IL-6 and TNF-a.46 A recent
study has shown that a-linoleic acid, EPA, and DHA reduce
inflammation in both the heart and the liver and prevent
cardiac fibrosis.40 The present study suggests that increased
liver DHA proportion may be a potential mechanism of anti-
inflammatory effects of LA in MCD-induced model of
NAFLD (Table 1).
Based on our results, it can be concluded that LA ame-
liorates lipid peroxidation and nitrosative stress in MCD
diet-induced hepatic steatosis through an increase in SOD
activity and GSH level. In addition, LA increases the pro-
portion of palmitic, stearic, arachidonic, and DHA in the
Table 1. The Effect of Methionine-Choline Deficient Diet and a-Lipoic Acid Treatment on Liver Free Fatty Acid Profile
Hepatic free fatty acid (%)
Group C16:0 C18:0 C18:1 n9 C18:1 n7 C18:2 n6 C20:4 n6 C22:5 n3 C22:6 n3
Control 22– 0.73 13.11– 0.67 10.25– 0.57 2.40 – 0.32 18.40– 0.74 15.45– 0.59 0.55 – 0.05 10.04– 0.43
MCD2 16.66– 1.17** 9.00 – 1.65** 14.44– 1.94** 0.91 – 0.19** 26.07– 2.54** 12.20– 2.21* 1.23 – 0.24** 9.13 – 0.76
MCD2 +LA 19.81– 0.81*## 15.27– 0.60* 9.87 – 1.01 0.84 – 0.08** 19.44– 1.36 15.64– 1.13 0.59 – 0.23 11.56– 1.15*
Animals were treated with MCD diet and MCD+LA (100 mg/kg daily i.p.) for 2 weeks (MCD2 and MCD2+LA groups, respectively). Since the normal
distribution of parameters was confirmed by Kolmogorov–Smirnov test, significance of the difference was estimated by using one-way ANOVA with Tukey’s post
hoc test (*P < .05, **P< .01 vs. control; ##P< .01 vs. MCD2 group).
C16:0, palmitic acid; C18:0, stearic acid; C18:1 n9, oleic acid; C18:1 n7, oleic acid isomer; C18:2 n6, linoleic acid; C20:4 n6, arachidonic acid; C22:5 n3,
docosapentaenoic acid (DPA); C22:6 n3, docosahexaenoic acid (DHA); LA, a-lipoic acid; MCD, methionine–choline deficient; ANOVA, analysis of variance.
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fatty liver. Increase in DHA may be considered a potential
mechanism of anti-inflammatory and antioxidant effects of
LA in MCD diet-induced NAFLD.
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